VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment

<p>Abstract</p> <p>Background</p> <p>Targeting tumor vasculature is a strategy with great promise in the treatment of many cancers. However, anti-angiogenic reagents that target VEGF/VEGFR2 signaling have met with variable results clinically. Among the possible reasons...

Full description

Bibliographic Details
Main Authors: Skowronski Karolina, Minhas Kanwal, Lacombe Kristen, Adamcic Una, Patten Steven G, Coomber Brenda L
Format: Article
Language:English
Published: BMC 2010-12-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/683

Similar Items

Similar Items